Physician profile
Sandy Xinyu Zhang-Nunes
NPI 1740434406
$149,492.47
in general payments reported to CMS, 2019-2025
13 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $6,832 · 2021: $173 · 2022: $4,205 · 2023: $54K · 2024: $55K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Honoraria: $45K · Travel and Lodging: $19K · Consulting Fee: $14K · Food and Beverage: $7,895 · Education: $1,339 · Gift: $33.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,400.00 |
| Honoraria | $45,328.50 |
| Travel and Lodging | $18,909.57 |
| Consulting Fee | $14,248.00 |
| Food and Beverage | $7,895.10 |
| Education | $1,338.64 |
| Gift | $33.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65,574.86 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $62,880.13 | 2019-2023 | Tepezza |
| Merz North America, INC. | $13,755.06 | 2022-2024 | Xeomin |
| Genentech USA, INC. | $3,315.25 | 2025 | |
| Abbvie INC. | $1,676.32 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $640.32 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $490.47 | 2023-2025 | |
| Galderma Laboratories, L.P. | $468.98 | 2022-2025 | Dysport |
| Alcon Vision LLC | $389.45 | 2019-2025 | Hydrus Microstent |
| Oyster Point Pharma, INC. | $164.03 | 2023 | Tyrvaya |
| Axogen | $137.60 | 2023 | Avance Nerve Graft |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Zhang-Nunes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.